Depression: INCREM Program Phase 3 Trial Reaches Primary Completion

By Hipa.ai Research · July 31, 2025

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026.

A Phase 3 clinical trial investigating the INtegral Cognitive REMediation Program (INCREM) for Depression reached its primary completion date on 2025-07-31. The study enrolled 296 participants.

Background

Depression is a prevalent mental illness with significant consequences for those affected. Its symptoms extend beyond mood swings, extreme sadness, apathy, and an inability to feel pleasure, often including sleep problems, eating disorders, and various physical issues. Crucially, depression frequently presents with cognitive symptoms that affect memory, concentration, and the ability to organize and solve problems. These cognitive impairments can significantly impact daily functioning and quality of life, making interventions that target these specific symptoms particularly relevant in the current treatment landscape.

Trial design

This study, identified as Phase 3, enrolled 296 participants diagnosed with Depression or Depressive Disorder. The trial's objective is to study the efficacy and safety of the INtegral Cognitive REMediation Program (INCREM) for depression. The program aims to address the cognitive symptoms often associated with the condition, such as difficulties with memory, concentration, and problem-solving abilities.

What this means

The primary completion of this Phase 3 trial signifies a key milestone in the development of the INtegral Cognitive REMediation Program (INCREM) for depression. While specific results are not yet available, reaching this stage indicates that the data collection for the primary endpoints has concluded for 296 participants. This progress is important for patients with depression, particularly those experiencing cognitive symptoms, as it moves the program closer to potential regulatory review and availability as a new therapeutic option.

Source

The information regarding this trial's primary completion was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06590025, titled "Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for Depression", was posted on 2025-07-31 on clinicaltrials.gov.